Valuation: Curis, Inc.

Market Cap 1.59M 1.42M 1.31M 1.19M 2.22M 151M 2.26M 15.79M 6.24M 78.9M 5.95M 5.82M 250M P/E 2026 *
-0.02x
P/E 2027 * -0.05x
Enterprise Value 1.59M 1.42M 1.31M 1.19M 2.22M 151M 2.26M 15.79M 6.24M 78.9M 5.95M 5.82M 250M EV / Sales 2026 *
-
EV / Sales 2027 * 0.17x
Free-Float
96.19%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Curis, Inc.

1 day-2.33%
1 week-1.13%
Current month-55.03%
1 month-54.62%
3 months-91.96%
6 months-96.76%
Current year-98.09%
1 week 0.36
Extreme 0.3625
0.42
1 month 0.32
Extreme 0.325
0.86
Current year 0.32
Extreme 0.325
24.2
1 year 0.32
Extreme 0.325
33
3 years 0.32
Extreme 0.325
349.8
5 years 0.32
Extreme 0.325
2,832
10 years 0.32
Extreme 0.325
7,440
Manager TitleAgeSince
Chief Executive Officer 59 24/09/2018
Director of Finance/CFO 54 05/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 01/11/2003
Chairman 84 16/05/2017
Director/Board Member 71 03/06/2010
Date Insider Type Main position Quantity % Market Cap. Importance
07/07/26 Free

Chief Executive Officer

110,090 0.2824%
07/07/26 Free

Director

6,800 0.0174%
07/07/26 Free

Chairman

6,800 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-1.13%-98.79%-99.53% 1.59M
+0.88%+1.18%+40.64%+74.91% 64.69B
-0.26%+7.23%+11.14%+74.78% 54.78B
+0.47%+3.52%+9.71%+100.95% 53.49B
-2.06%+2.90%+25.83%+48.36% 45.98B
-1.79%+0.19%+17.58%+123.62% 42.94B
-1.65%+0.96%+217.12%+823.66% 40.08B
-2.26%-2.06%+15.38%+45.14% 33.52B
+0.22%-4.77%+26.59%+0.55% 23.97B
+12.10%+16.60%+58.50%+46.15% 23.67B
Average +0.33%+1.49%+32.37%+123.86% 38.31B
Weighted average by Cap. +0.12%+2.59%+44.22%+150.09%

Financials

2026 *2027 *
Net sales - 9.25M 8.27M 7.65M 6.93M 12.97M 880M 13.18M 92.09M 36.43M 460M 34.72M 33.98M 1.46B
Net income -52.02M -46.51M -43.03M -38.96M -72.93M -4.95B -74.12M -518M -205M -2.59B -195M -191M -8.2B -45.23M -40.45M -37.42M -33.88M -63.41M -4.3B -64.45M -450M -178M -2.25B -170M -166M -7.13B
Net Debt - -
Projected Income Statement - Annual - Curis, Inc.
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
22
Date Price Change Volume
26/10/26 $0.3773 -2.33% 315,490
23/10/26 $0.3863 -4.59% 66,864
22/10/26 $0.4049 +3.29% 158,201
21/10/26 $0.3920 -1.90% 96,019
20/10/26 $0.3996 +4.72% 217,997
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Curis, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.3863USD
Average target price
42.67USD
Spread / Average Target
+10,944.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Curis, Inc.
  1. Stock Market
  2. Stocks
  3. CRIS Stock